PE20010302A1 - COMBINACION DE INHIBIDORES DE MTP E INHIBIDORES DE HMG-CoA REDUCTASA - Google Patents
COMBINACION DE INHIBIDORES DE MTP E INHIBIDORES DE HMG-CoA REDUCTASAInfo
- Publication number
- PE20010302A1 PE20010302A1 PE2000000625A PE0006252000A PE20010302A1 PE 20010302 A1 PE20010302 A1 PE 20010302A1 PE 2000000625 A PE2000000625 A PE 2000000625A PE 0006252000 A PE0006252000 A PE 0006252000A PE 20010302 A1 PE20010302 A1 PE 20010302A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- inhibitors
- combination
- phenyl
- cycloalkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE AL USO DE UNA COMBINACION DE a)UN INHIBIDOR DE MTP TAL COMO 1)UN COMPUESTO (A1); DONDE: R1 Y R2 FORMAN UN FENILO, PIRIDILO O UN GRUPO a; R8 ES H, ALQUILO C1-C4; R3 Y R4 FORMAN UN FENILO, CICLOALQUENO, OXOCICLOALQUENO DE 4-8 MIEMBROS; D ES H, CICLOALQUILO C4-C12, ALQUILO C1-C12; E ES CO, CS; L ES O, S, NR9; R9 ES H, ALQUILO C1-C6; R5 ES FENILO, HETEROCICLO 5-7 ESLABONES; R6 ES H, CARBOXI, ALCOXICARBONILO C1-C5, ALQUILO C1-C6; R7 ES H; O R6 Y R7 JUNTOS FORMAN =O, 2)UN COMPUESTO A2; A ES UN GRUPO b, c, ENTRE OTROS; L Y M SON H, HALOGENO, TRIFLUOROMETILO, ENTRE OTROS; Q ES N, CH; T ES SO2, CO, O, S; V ES O, S; R5-R8 SON H, ALQUILO C1-C6, R9 ES TRIFLUOROMETILO, BENCILO, HETEROCICLO; a ES 0-2; R10 ES ALQUILO, ALQUENILO; D Y E SON H, HALOGENO, ENTRE OTROS; Z ES O, S; R1 ES CICLOALQUILO C3-C10, ALQUILO C1-C10, ENTRE OTROS; R2 ES H, ALQUILO; R3 ES H, ALQUILO, CICLOALQUILO C3-C7; R4 ES H, CH2-OH; DE PREFERENCIA 2-CICLOPENTIL-2-[4-(2,4-DIMETILPIRIDO[2,3-b]INDOL-9-ILMETIL)FENIL]-N-(2-HIDROXI-1-FENILETIL)ACETAMIDA, ENTRE OTROS; b)INHIBIDORES DE HMGCoA TAL COMO ATORVASTATINA, CERIVASTATINA, SIMVASTATINA, PRAVASTATINA, LOVASTATINA, FLUVASTATINA, ITAVASTATINA. LA COMBINACION PUEDE SER UTIL PARA EL TRATAMIENTO DE ENFERMEDADES DEL SISTEMA CARDIOCIRCULATORIO, ARTERIOSCLEROSIS, ENFERMEDADES CORONARIAS, HIPERCOLESTEROLEMIA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19929065A DE19929065A1 (de) | 1999-06-25 | 1999-06-25 | Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010302A1 true PE20010302A1 (es) | 2001-04-12 |
Family
ID=7912459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000625A PE20010302A1 (es) | 1999-06-25 | 2000-06-23 | COMBINACION DE INHIBIDORES DE MTP E INHIBIDORES DE HMG-CoA REDUCTASA |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1196194A2 (es) |
| JP (1) | JP2003503342A (es) |
| AR (1) | AR028996A1 (es) |
| AU (1) | AU5680900A (es) |
| CA (1) | CA2376881A1 (es) |
| DE (1) | DE19929065A1 (es) |
| DO (1) | DOP2000000022A (es) |
| GT (1) | GT200000099A (es) |
| PE (1) | PE20010302A1 (es) |
| SV (1) | SV2004000109A (es) |
| UY (1) | UY26218A1 (es) |
| WO (1) | WO2001000183A2 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10030375A1 (de) * | 2000-06-21 | 2002-01-03 | Bayer Ag | Verwendung von MTP-Inhibitoren zur Senkung von ppTRL |
| IL161134A0 (en) * | 2002-02-28 | 2004-08-31 | Japan Tobacco Inc | Ester compound and medical use thereof |
| EP1669345A4 (en) * | 2003-08-29 | 2008-02-20 | Japan Tobacco Inc | ESTER DERIVATIVE AND MEDICAL USE THEREOF |
| US8101774B2 (en) | 2004-10-18 | 2012-01-24 | Japan Tobacco Inc. | Ester derivatives and medicinal use thereof |
| FR2884831B1 (fr) * | 2005-04-22 | 2007-08-10 | Merck Sante Soc Par Actions Si | Methode de criblage de composes inhibiteurs de la mtp |
| DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| US10905667B2 (en) | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
| CN109053927A (zh) * | 2018-08-08 | 2018-12-21 | 中山大学 | 一种含维生素b12基团的两亲性海藻酸钠衍生物及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4435477A1 (de) * | 1994-10-04 | 1996-04-11 | Bayer Ag | Cycloalkano-indol- und -azaindol-derivate |
| DE19546919A1 (de) * | 1995-12-15 | 1997-06-19 | Bayer Ag | N-Heterocyclisch substituierte Phenylessigsäure-Derivate |
| DE19546918A1 (de) * | 1995-12-15 | 1997-06-19 | Bayer Ag | Bicyclische Heterocyclen |
| DE19615265A1 (de) * | 1996-04-18 | 1997-12-04 | Bayer Ag | Neue Pyridazino-, Pyrimido-, Pyrazino- und Triazino-indole |
| CA2272719C (en) * | 1996-11-27 | 2002-10-01 | Pfizer Limited | Apo b-secretion/mtp inhibitory amides |
| EP1024804A4 (en) * | 1997-05-01 | 2001-03-21 | Bristol Myers Squibb Co | MTP INHIBITORS AND FAT-SOLUBLE VITAMIN THERAPEUTICS TO REDUCE SERUM LIPIDS |
-
1999
- 1999-06-25 DE DE19929065A patent/DE19929065A1/de not_active Withdrawn
-
2000
- 2000-06-13 CA CA002376881A patent/CA2376881A1/en not_active Abandoned
- 2000-06-13 WO PCT/EP2000/005410 patent/WO2001000183A2/de not_active Application Discontinuation
- 2000-06-13 JP JP2001505893A patent/JP2003503342A/ja active Pending
- 2000-06-13 AU AU56809/00A patent/AU5680900A/en not_active Abandoned
- 2000-06-13 EP EP00942056A patent/EP1196194A2/de not_active Withdrawn
- 2000-06-21 GT GT200000099A patent/GT200000099A/es unknown
- 2000-06-22 AR ARP000103129A patent/AR028996A1/es unknown
- 2000-06-23 UY UY26218A patent/UY26218A1/es not_active Application Discontinuation
- 2000-06-23 PE PE2000000625A patent/PE20010302A1/es not_active Application Discontinuation
- 2000-06-23 SV SV2000000109A patent/SV2004000109A/es unknown
-
2008
- 2008-04-11 DO DO2000000022A patent/DOP2000000022A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY26218A1 (es) | 2001-01-31 |
| JP2003503342A (ja) | 2003-01-28 |
| AU5680900A (en) | 2001-01-31 |
| SV2004000109A (es) | 2004-05-07 |
| DE19929065A1 (de) | 2000-12-28 |
| EP1196194A2 (de) | 2002-04-17 |
| WO2001000183A2 (de) | 2001-01-04 |
| AR028996A1 (es) | 2003-06-04 |
| DOP2000000022A (es) | 2008-08-15 |
| WO2001000183A3 (de) | 2001-05-10 |
| CA2376881A1 (en) | 2001-01-04 |
| GT200000099A (es) | 2001-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20011294A1 (es) | Composiciones farmaceuticas de agonistas/antagonistas de estrogeno y estatinas para tratar la osteoporosis y reducir el colesterol | |
| PE20001054A1 (es) | 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-amino sustituidas | |
| PE20030497A1 (es) | Combinaciones de un inhibidor de pde 5 y otros agentes activos | |
| DE60233884D1 (de) | 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidon-derivate als pde-4-hemmer zur behandlung von neurologischen syndromen | |
| TR199900400T2 (xx) | Heterosiklik metaloproteaz inhibit�rleri. | |
| PE20060777A1 (es) | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas | |
| TR199900382T2 (xx) | Heterosiklik metaloproteaz inhibit�rleri. | |
| ATE510837T1 (de) | Caspase inhibitoren und deren verwendung | |
| PE20050389A1 (es) | Compuestos de quinolina y quinoxalina | |
| PE20010302A1 (es) | COMBINACION DE INHIBIDORES DE MTP E INHIBIDORES DE HMG-CoA REDUCTASA | |
| TR199900383T2 (xx) | 1,3-Diheterosiklik metaloproteaz inhibit�rleri. | |
| ECSP045368A (es) | "antagonistas de los receptores de trombina" | |
| ES2184280T3 (es) | Compuestos de indol como inhibidores de cox-2'. | |
| ATE377010T1 (de) | Caspase-inhibitoren und ihre verwendungen | |
| PA8444301A1 (es) | Compuestos de quinolina y de quinazolina utiles en terapia | |
| MA27182A1 (fr) | Derives de thiazole et d'oxazole qui modulent l'activite de ppar. | |
| AR049696A1 (es) | Derivados de indol | |
| CO5611143A2 (es) | Profarmacos de fosfatos de fluorooxindoles | |
| AR022824A1 (es) | Inhibidores de metaloproteasa dihetero-sustituida | |
| PE20000017A1 (es) | Combinaciones de estatina-eter carboxialquilico | |
| ATE444299T1 (de) | Neue boronatester | |
| ATE342261T1 (de) | Pyranderivate als inhibitoren von ace und nep | |
| PE20020436A1 (es) | Derivados de tetrahidropirano como antagonistas del receptor de neuroquinina 1 (nk-1) | |
| DE60014343D1 (de) | N-(2-phenyl-4-amino-butyl)-1-naphthamide als neurokinin-1 rezeptorantagonisten | |
| ATE521610T1 (de) | Spiroverbindungen und -verfahren zur modulation von chemokin-rezeptor-aktivität |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |